Edition:
United States

Foamix Pharmaceuticals Ltd (FOMX.OQ)

FOMX.OQ on NASDAQ Stock Exchange Global Market

5.47USD
18 Jun 2018
Change (% chg)

$0.16 (+3.01%)
Prev Close
$5.31
Open
$5.30
Day's High
$5.57
Day's Low
$5.17
Volume
22,422
Avg. Vol
27,923
52-wk High
$7.43
52-wk Low
$4.19

Chart for

About

Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and... (more)

Overall

Beta: 1.88
Market Cap(Mil.): $215.08
Shares Outstanding(Mil.): 40.50
Dividend: --
Yield (%): --

Financials

  FOMX.OQ Industry Sector
P/E (TTM): -- 240.92 34.18
EPS (TTM): -2.06 -- --
ROI: -95.06 -5.87 13.17
ROE: -96.10 -7.71 15.15

BRIEF-Foamix Reports Fiscal Year 2017 Financial Results And Provides Corporate Update

* FOAMIX REPORTS FISCAL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Feb 28 2018

BRIEF-Tamarkin Medical Reports 7.3 Percent Passive Stake In Foamix Pharmaceuticals

* TAMARKIN MEDICAL INNOVATIONS LTD REPORTS 7.3 PERCENT PASSIVE STAKE IN FOAMIX PHARMACEUTICALS AS OF DECEMBER 31, 2017 - SEC FILING Source text: (http://bit.ly/2so9g8s) Further company coverage:

Feb 13 2018

BRIEF-Foamix Announces Positive Results From Late Stage Acne Treatment Study

* FOAMIX ANNOUNCES POSITIVE RESULTS FROM PHASE 3 OPEN-LABEL SAFETY EXTENSION EVALUATING FMX-101 TOPICAL MINOCYCLINE FOAM FOR TREATMENT UP TO 1 YEAR Source text for Eikon: Further company coverage:

Jan 04 2018

BRIEF-Foamix Names David Domzalski As A Member Of Company Board

* FOAMIX NAMES MR. DAVID DOMZALSKI AS A MEMBER OF THE BOARD OF FOAMIX PHARMACEUTICALS

Jan 03 2018

Earnings vs. Estimates